Neuronal Ceroid Lipofuscinosis 8 C1838570
NCL8 is a genetic disorder that causes lipopigment buildup in cells, leading to progressive neurological damage. It typically begins in childhood with seizures and developmental regression. Treatment addresses symptoms but cannot slow the underlying disease progression.
Key facts at a glance
- ICD-10
- G31.82
- ICD-11
- 8A00.0
- Body system
- neurologic
- Severity
- fatal
- Chronic
- true
Signs and symptoms
Common signs and symptoms that may indicate this condition.
Warning signs - seek immediate care
Generalized symptoms
Progressive symptoms that can become life-threatening without treatment.
Seek immediate medical attention if symptoms worsen.
Visual deterioration
Myoclonic seizures
Cognitive decline
(neurologic)Peripheral neuropathy
(neurologic)Diagnosis and tests
How this condition is diagnosed and what test results mean.
Initial screening tests
Standard diagnostic workup
Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]
Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]
Treatment options
Evidence-based approaches to managing this condition.
First-line treatments
Minimally invasive procedural intervention
Treatment may require specialized care, hospitalization, or long-term management under medical supervision.
Seizure control therapy
Anticonvulsant medications are essential for managing seizures associated with neuronal ceroid lipofuscinosis 8. Treatment requires careful selection and monitoring to achieve optimal seizure control while minimizing side effects.
Adaptive physical rehabilitation
Physical therapy programs are customized to maintain strength, balance, and mobility for as long as possible. Therapists introduce appropriate assistive devices and teach families safe handling techniques as motor function declines.
Additional treatment options
Nutritional support and management
Registered dietitian consultation ensures adequate caloric and nutritional intake as eating difficulties develop. Dietary modifications may include food texture changes, smaller frequent meals, and supplemental nutrition options.
dietaryAirway and feeding management
When swallowing difficulties become severe, placement of a gastrostomy tube provides reliable nutrition delivery and reduces aspiration risk. Combined with respiratory monitoring, this procedure addresses critical safety concerns.
procedurePalliative care and family support
Integrating palliative care services early provides comprehensive support addressing physical symptoms, emotional needs, and care coordination. This approach ensures quality of life remains the central focus throughout the illness course.
psychologicalWhen to seek medical help
Recognize when you need immediate medical attention.
Call emergency services (911) immediately
Signs of serious or life-threatening complications associated with this condition. Immediate medical evaluation is required.
Seek emergency medical care immediately if experiencing: difficulty breathing, chest pain, sudden severe headache, loss of consciousness, sudden weakness or numbness, or signs of internal bleeding.
Frequently asked questions
Common questions about this topic.
What is Neuronal Ceroid Lipofuscinosis 8 C1838570?
Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]
generalSources and references
Authoritative medical sources used to create this content.
Mole SE, Cotman SL, Mangano R. Guidelines for the diagnosis and management of neuronal ceroid lipofuscinosis type 8 (CLN8 disease). Orphanet J Rare Dis. 2022.
Jalanko A, Braulke T. Neuronal ceroid lipofuscinoses: the increasing spectrum of an old disease. Biochim Biophys Acta Mol Basis Dis. 2019.
Schulz A, Kohlschütter A, Mink J, et al. Enzyme replacement therapy in patients with neuronal ceroid lipofuscinosis type 8: a phase 1/2 clinical trial. Lancet Neurol. 2020.
Williams RE, Adams HR, Blohm M, et al. Management strategies for CLN8 disease: a systematic review of the literature. J Inherit Metab Dis. 2021.
Medication Comparisons
Compare medications used to treat Neuronal Ceroid Lipofuscinosis 8 C1838570. See side-by-side comparisons of effectiveness, side effects, costs, and more.
View Medication ComparisonsThis information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy